Links to 12 New HCV Info and Treatment Articles (mainly from EASL)

[Guest guest]

Impact of amino acid substitutions in hepatitis C virus genotype 1b core region

on liver steatosis and glucose tolerance in non-cirrhotic patients without overt

diabetes (pages 836–842)

Yoshio Sumida, Kazuyuki Kanemasa, Tasuku Hara, Yutaka Inada, Kyoko Sakai,

Shunsuke Imai, Naohisa Yoshida, Kohichiroh Yasui, Yoshito Itoh, Takeshi Okanoue

and Toshikazu Yoshikawa

Article first published online: 13 APR 2011 | DOI:

10.1111/j.1440-1746.2010.06568.x

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene

determines response of hepatitis C virus patients to interferon therapy (pages

843–850)

Mostafa K El Awady, Mohamed A Anany, Gamal Esmat, Naglaa Zayed, Ashraf A Tabll,

Amr Helmy, Abdel Rahman El Zayady, Mohga S Abdalla, Hayat M Sharada, Maissa El

Raziky, Wafaa El Akel, Shadia Abdalla and Noha G Bader El Din

Article first published online: 13 APR 2011 | DOI:

10.1111/j.1440-1746.2010.06605.x

HIVandHepatitis.com

BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon

SUMMARY

Most prior non-responders with HCV genotype 1 achieved sustained response with a

quadruple combination containing 2 experimental agents plus pegylated

interferon/ribavirin, and nearly 40% did so using only the 2 oral drugs --

BMS-790052 and BMS-650032 -- researchers reported at EASL 2011.

BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment

SUMMARY

About 90% of treatment-naive genotype 1 hepatitis C patients achieved sustained

response at 12 weeks post-treatment using the experimental HCV protease

inhibitor BMS-790052 plus pegylated interferon/ribavirin, researchers reported

at EASL 2011.

Liver Disease Progression in HIV/HCV Coinfected People

SUMMARY

Liver stiffness measured by FibroScan is a good predictor of liver cancer,

end-stage liver disease or death among people with HIV/HCV coinfection,

researchers reported as EASL 2011.

Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve

Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon

a-2a and Ribavirin in the PILLAR Study

J Aerssens and others. EASL 2011.

Treatment outcome and resistance analysis in HCV genotype 1 patients previously

exposed to TMC435 monotherapy and re-treated with TMC435 in combination with

PegIFNa-2a/ribavirin

O Lenz and others. EASL 2011.

The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV

infection who have failed previous PegIFN/RBV treatment: Week 24 interim

analysis

S Zeuzem and others. EASL 2011.

First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in

Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV

Genotype 1 Subjects

S Pol and others. EASL 2011.

A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir

(GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV

Infection

E Lawitz and others. EASL 2011.

Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451

A Corsa and others. EASL 2011.

Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA)

Assessments in Patients with Chronic Hepatitis B (CHB)

S Fung and others. EASL 2011

First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in

Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV

Genotype 1 Subjects

S Pol and others. EASL 2011.

A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir

(GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV

Infection

E Lawitz and others. EASL 2011.

Treatment outcome and resistance analysis in HCV genotype 1 patients previously

exposed to TMC435 monotherapy and re-treated with TMC435 in combination with

PegIFNa-2a/ribavirin

O Lenz and others. EASL 2011.

[Guest guest]

Impact of amino acid substitutions in hepatitis C virus genotype 1b core region

on liver steatosis and glucose tolerance in non-cirrhotic patients without overt

diabetes (pages 836–842)

Yoshio Sumida, Kazuyuki Kanemasa, Tasuku Hara, Yutaka Inada, Kyoko Sakai,

Shunsuke Imai, Naohisa Yoshida, Kohichiroh Yasui, Yoshito Itoh, Takeshi Okanoue

and Toshikazu Yoshikawa

Article first published online: 13 APR 2011 | DOI:

10.1111/j.1440-1746.2010.06568.x

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene

determines response of hepatitis C virus patients to interferon therapy (pages

843–850)

Mostafa K El Awady, Mohamed A Anany, Gamal Esmat, Naglaa Zayed, Ashraf A Tabll,

Amr Helmy, Abdel Rahman El Zayady, Mohga S Abdalla, Hayat M Sharada, Maissa El

Raziky, Wafaa El Akel, Shadia Abdalla and Noha G Bader El Din

Article first published online: 13 APR 2011 | DOI:

10.1111/j.1440-1746.2010.06605.x

HIVandHepatitis.com

BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon

SUMMARY

Most prior non-responders with HCV genotype 1 achieved sustained response with a

quadruple combination containing 2 experimental agents plus pegylated

interferon/ribavirin, and nearly 40% did so using only the 2 oral drugs --

BMS-790052 and BMS-650032 -- researchers reported at EASL 2011.

BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment

SUMMARY

About 90% of treatment-naive genotype 1 hepatitis C patients achieved sustained

response at 12 weeks post-treatment using the experimental HCV protease

inhibitor BMS-790052 plus pegylated interferon/ribavirin, researchers reported

at EASL 2011.

Liver Disease Progression in HIV/HCV Coinfected People

SUMMARY

Liver stiffness measured by FibroScan is a good predictor of liver cancer,

end-stage liver disease or death among people with HIV/HCV coinfection,

researchers reported as EASL 2011.

Impact of IL28B Genotype and Pre-treatment Serum IP-10 in Treatment-Naïve

Genotype 1 HCV Patients Treated with TMC435 in Combination with Peginterferon

a-2a and Ribavirin in the PILLAR Study

J Aerssens and others. EASL 2011.

Treatment outcome and resistance analysis in HCV genotype 1 patients previously

exposed to TMC435 monotherapy and re-treated with TMC435 in combination with

PegIFNa-2a/ribavirin

O Lenz and others. EASL 2011.

The ASPIRE Trial: TMC435 in treatment-experienced patients with genotype 1 HCV

infection who have failed previous PegIFN/RBV treatment: Week 24 interim

analysis

S Zeuzem and others. EASL 2011.

First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in

Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV

Genotype 1 Subjects

S Pol and others. EASL 2011.

A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir

(GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV

Infection

E Lawitz and others. EASL 2011.

Preclinical Properties of the Novel HCV NS3 Protease Inhibitor GS-9451

A Corsa and others. EASL 2011.

Reduced Bone Mineral Density Derived from Dual X-ray Absorptiometry (DEXA)

Assessments in Patients with Chronic Hepatitis B (CHB)

S Fung and others. EASL 2011

First Report of SVR12 for a NS5A Replication Complex Inhibitor, BMS-790052, in

Combination With PegIFNá-2a and RBV: Phase IIA Trial in Treatment-Naive HCV

Genotype 1 Subjects

S Pol and others. EASL 2011.

A Phase 2b Trial Comparing 24 to 48 Weeks Treatment with Tegobuvir

(GS-9190)/PEG/RBV to 48 Weeks Treatment with PEG/RBV for Chronic Genotype 1 HCV

Infection

E Lawitz and others. EASL 2011.

Treatment outcome and resistance analysis in HCV genotype 1 patients previously

exposed to TMC435 monotherapy and re-treated with TMC435 in combination with

PegIFNa-2a/ribavirin

O Lenz and others. EASL 2011.